Proteinase 3 (PR3) is the major antigen for anti-neutrophil cytoplasmic antibodies (ANCAs) in the systemic autoimmune vasculitis, granulomatosis with polyangiitis (GPA). PR3-targeting ANCAs (PR3-ANCAs) recognize different epitopes on PR3 and are thought to be pathogenic for the development of the necrotizing vasculitis. To identify epitopes recognized by PR3-ANCAs, we pursued a strategy based on human-murine chimeric PR3 mutants. Interestingly, rather than observing reduced binding of PR3-ANCAs to Epitope 5 on a PR3 mutant (iHm5-Val 103 ) with chimeric mutations in Epitope 5, we found substantially increased binding of the majority of PR3-ANCAs to iHm5-Val 103 compared with the PR3 mutant (iPR3-Val 103 ) clinically used to detect PR3-ANCAs. More interestingly, using iHm5-Val 103 we identified a monoclonal antibody (moANCA518) from a patient with GPA that bound selectively to iHm5-Val 103 . Inhibition experiments using epitope-specific monoclonal antibodies and their antigen-binding fragments mapped the binding sites of moANCA518 and PR3-ANCAs (from patients displaying preferential binding to iHm5-Val 103 over iPR3-Val 103 ) to Epitope 3 on iHm5-Val 103 , a mutationfree epitope located far from the mutation sites in Epitope 5. These results demonstrate that the selective binding of moANCA518 (and likely the preferential binding of PR3-ANCAs from patients) to iHm5-Val 103 is conferred by increased antigenicity of Epitope 3 on iHm5-Val 103 caused by distal mutations, indicating that PR3-ANCAs bind to epitopes of a folded antigen conducive to allosteric effects of mutations-a previously unrecognized characteristic with implications for studying antibody-mediated autoimmune diseases and novel treatment approaches.
Introduction
Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) comprises a group of systemic small-vessel vasculitis syndromes including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA) [1] . The two major target antigens for the ANCAs in vasculitis are proteinase 3 (PR3) and myeloperoxidase (MPO) [2] [3] [4] . Testing for the presence of ANCAs has become indispensable in the evaluation of patients suspected of having AAV [5] . Patients with PR3-targeting ANCAs (PR3-ANCAs) are at a much higher risk for relapses than patients with myeloperoxidase-targeting ANCAs (MPO-ANCAs). In addition, PR3-ANCA positivity and rising titers following treatment portend relapses, particularly for patients with renal disease and other disease manifestations of capillaritis [6] [7] [8] . The binding of PR3-ANCAs to PR3 has many well-documented pro-inflammatory effects, and PR3-ANCAs are thought to play a pathogenic role for the development of necrotizing vasculitis [9] [10] [11] .
The oligoclonal PR3-ANCAs from patients with GPA are known to bind to different epitopes of the folded PR3 antigen, whereas denatured PR3 or improperly folded recombinant PR3 generated in non-mammalian expression systems do not bind PR3-ANCAs reliably [12] [13] [14] .
Consistently, studies of continuous epitope mapping of PR3-ANCAs using oligopeptides have generated inconclusive results [15] [16] [17] [18] .
In this context, we performed instead discontinuous epitope mapping of anti-PR3 monoclonal antibodies (moAbs) and PR3-ANCAs using human-murine chimeric mutants to obtain mechanistic insights into how interactions of PR3 with its environment during inflammation are modified by PR3-ANCAs and potentially targetable by therapeutics [19] .
Herein, the iPR3-Val 103 mutant represents the most prevalent wild-type PR3 polymorphism (Val103) and contains the Ser195Ala mutation at the active site ( Fig. 1) to avoid potential enzymatic degradation of ANCAs or PR3-capturing moAbs by PR3 in immunoassays or cytotoxicity when PR3 is expressed in the 293 kidney epithelial cells [19] [20] [21] [22] [23] . Because it has the same folded conformation of the wild-type mature PR3, iPR3-Val 103 has been used for two decades as a standard PR3 antigen for sensitive and specific PR3-ANCA detection by immunoassay [7, 21, [24] [25] [26] [27] [28] [29] .
In our epitope mapping study, we developed a human-murine chimeric mutant of iPR3-Val 103 (iHm5-Val 103 ; formerly referred to as Hm5 [19] ) to investigate the involvement of Epitope 5 on PR3-an epitope defined by binding of a group of moAbs including MCPR3-7-in the binding of PR3 to neutrophil membranes [19, 30, 31] . Because this mutant has its three hydrophobic/aromatic residues (Ala146, Trp218, and Leu223; Fig. 1 ) of human PR3 replaced by their murine hydrophilic counterparts (Thr146, Arg218, and Gln223), we expected that the PR3-ANCAs would show reduced binding to the mutated epitopes on iHm5-Val 103 relative to iPR3-Val 103 . Unexpectedly, we found that PR3-ANCAs either have similar binding to both antigens or preferential binding to iHm5-Val 103 .
Informed by this background, we conducted the present study using large well-defined patient cohorts to (i) determine the scope of this preferential binding of PR3-ANCAs to iHm5-Val 103 , (ii) analyze the potential utility of iHm5-Val 103 as an in vitro antigen for PR3-ANCA detection, and (iii) identify the epitope(s) involved in this substantially enhanced antigenicity of iHm5-Val 103 for PR3-ANCAs for a better understanding of mechanistic details with relevance to the cause of antibody-mediated autoimmune diseases and the design of potential novel treatment approaches.
Material and methods
Reagents were obtained from Sigma (St. Louis, MO) unless specified otherwise. The human epithelial kidney cell line 293 used for the expression of recombinant PR3 mutants was obtained from ATCC (Rockville, MD).
Recombinant PR3 mutants
The cDNA constructs coding for iPR3-Val 103 and iHm5-Val 103 and their expression in HEK293 cells were described in detail elsewhere [19, 26] . Both mutants carry a carboxyterminal cmyc-peptide extension and a poly-His peptide extension for anchoring in solid phase immunoassays and purification using nickel columns from GE Healthcare (Chicago, IL) as previously described and specified below [19, [26] [27] [28] 32 ].
Immunoassays
For according to package insert, and exposed as indicated. Alternatively, epitope specific anti-PR3 moAbs (see below) were coated to Maxisorp® plates at concentrations of 2.0-4.0 μg/mL in NaHCO 3 overnight at 4 ºC to capture the PR3 mutants.
The anchor ELISA method for IgG PR3-ANCAs was described previously for IgA PR3-ANCAs [32] and is conceptually similar to the capture ELISA utilizing the C-terminal cmycpeptide extension of a PR3 mutant [26, 27] were determined as 0.105 and 0.107 OD, respectively.
Serum samples
The 30 serum samples from normal donors used for the determination of the normal (negative) range of the anchor ELISA for PR3-ANCA detection using the PR3 mutants as antigen were obtained from the Clinical Immunology Laboratory of Mayo Clinic, Rochester, MN. Three hundred serum samples from healthy octogenarians used for the specificity analyses were obtained from the Mayo Clinic Biospecimen repository. No patient identifiers or clinical data about these individuals were available to the investigators. The use of these serum samples for this study was approved by the Mayo Clinic Institutional Review Board.
Serum samples from patients with ANCA-associated vasculitis used in this study were collected during the Wegener's Granulomatosis Etanercept Trial (WGET) and during the Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis trial (RAVE). Details of the WGET and RAVE protocols, patient characteristics and trial results were described elsewhere [33] [34] [35] . Participants of both trials had provided written consent for the use of their serum samples in ancillary studies.
Generation of moANCA518
DNA barcode-enabled sequencing of the antibody repertoire was performed on plasmablasts derived from 5 participants in the RAVE study at baseline, at time of remission and at time of subsequent relapse as described for rheumatoid arthritis and Sjögren syndrome [36, 37] . Phylograms of the antibody repertoires revealed clonal families of affinity matured antibodies with shared heavy and light chain VJ usage, and 25 antibodies were selected for recombinant expression [36] . These 25 recombinant human monoclonal antibodies were tested for reactivity with ANCA target antigens, including MPO [32] , human neutrophil elastase (HNE) [38] [39] [40] , iPR3-Val 103 , and iHm5-Val 103 in parallel, by the anchor ELISA using recombinant antigens carrying a C-terminal poly-His tag.
Monoclonal antibodies and antigen-binding fragments
The moAb PR3G-2 (targeting Epitope 1) was obtained from the Kallenberg group, and the moAb WGM2 (targeting Epitope 3) was purchased from Hycult Biotech Inc. (Wayne, PA) [19, 41, 42] . The moAbs MCPR3-2 (targeting Epitope 4), MPR3-3 (targeting Epitope 3) and MCPR3-7 (targeting Epitope 5) that were generated by the Specks group were described and characterized in detail elsewhere [19, 24, 26] .
The Pierce™ Fab Preparation Kit from Thermo Fisher Scientific was used to generate the antigen-binding fragment (Fab) from 1.0 mg of a moAb (moANCA518, MCPR3-2, MCPR3-3, or MCPR3-7) following the manufacturer's protocol.
Statistical analysis
IBM ® SPSS ® Statistics for MacOS, version 25 (IBM, Armonk, NY, USA) was used to calculate the means and standard errors of 3-5 repeat experiments and to compare the means between groups with the two-tailed paired t-test.
Results

Preferential binding of PR3-ANCAs to iHM5-Val 103 over iPR3-Val 103
Using the net absorbance as a measure of the reactivity of a serum sample with an antigen, we found that the reactivities of IgG PR3-ANCA positive serum samples with iHm5-Val 103 were either equal or higher than those with iPR3-Val 103 in an anchor ELISA ( Fig. 2) . Of the 178 serum samples obtained from the WGET participants at enrollment, 148 had previously tested positive for PR3-ANCA in at least one of several immunoassays for PR3-ANCAs [33] .
By the anchor ELISA, 144 samples tested positive for IgG PR3-ANCAs with iHm5-Val 103 , and 135 were positive with iPR3-Val 103 ( Table 1 and Supplementary Figure) . Of the 135 samples that reacted with both antigens, 108 (80%) had higher reactivities with iHm5-Val 103 than with iPR3-Val 103 , and 41 (30%) of the samples had reactivities with iHm5-Val 103 that were more than double the reactivities with iPR3-Val 103 (Table 1 and Supplementary Figure) .
To confirm these results in an independent cohort, we also analyzed 129 serum samples, which had previously tested positive for PR3-ANCAs in at least one immunoassay and were obtained from the participants in the RAVE study at the time of enrollment [34, 35] . Of these, 128 samples showed reactivity with iHm5-Val 103 and 126 samples reacted with both iHm5-Val 103 and iPR3-Val 103 . The reactivities with iHm5-Val 103 of 33 (26%) of these 126 samples were more than double the reactivities with iPR3-Val 103 ( Table 1 and Supplementary Figure) . The single serum sample from the WGET cohort and the three serum samples from the RAVE cohort that showed higher reactivity with iPR3-Val 103 than with iHm5-Val 103 all yielded very high net absorbance values for both antigens, and on repeat testing results were consistenly slightly lower with iHm5-Val 103 with the differences for each simple being just above the intra-assay coefficient of variance of the assay of 5% (data not shown).
To further evaluate whether the preferential binding of PR3-ANCA to iHm5-Val 103 over iPR3-Val 103 is of potential clinical utility, we explored the sensitivity and specificity of the anchor ELISA using iHm5-Val 103 in defined cohorts.
Of the 14 WGET participants who had previously consistently tested negative for PR3-ANCAs in other assays [28] , enrollment serum samples of two patients (14%) were positive in the anchor ELISA using iHm5-Val 103 , indicating that in a sizable number of patients with GPA that were previously labeled as "ANCA-negative," PR3-ANCA can be detected with the iHm5- We also determined the prevalence of PR3-ANCAs in a population of 300 octogenarians without AAV by the anchor ELISA using iHm5-Val 103 and iPR3-Val 103 because the frequency of autoantibodies without a corresponding disease is reportedly increasing with age [43] . Only one sample from this population showed weak IgG PR3-ANCA reactivity with iHm5-Val 103 by the anchor ELISA (net absorbance of 0.173 OD), and two different patients showed reactivity using iPR3-Val 103 (net absorbances of 0.115 and 0.245 OD, respectively).
To determine whether using iHm5-Val 103 in the anchor ELISA would allow an earlier detection of PR3-ANCA seroconversion during serial follow-up of patients with AAV, we compared the seroconversion patterns of 33 participants from the WGET and found that PR3-ANCA seroconversion detected by the anchor ELISA using iPR3-Val 103 could not be detected at an earlier quarterly study visit when using iHm5-Val 103 .
We 
Selective binding of moANCA518 to iHm5-Val 103
Twenty-five human moAbs derived from plasmablasts of patients with PR3-ANCA positive relapsing AAV were screened for binding to ANCA target antigens by the anchor ELISA using iPR3-Val 103 , iHm5-Val 103 , and two other ANCA-targeting antigens (MPO and HNE). Interestingly, we found that one such moAb (moANCA518) exhibited concentrationdependent binding to iHm5-Val 103 in the anchor ELISA (Fig. 3A) , whereas none of these moAbs bound to iPR3-Val 103 , MPO, or HNE. We confirmed the binding of moANCA518 to iHm5-Val 103 but not to iPR3-Val 103 by Western blot under non-reducing conditions (Fig. 3B) . We also confirmed the selective binding of moANCA518 to iHm5-Val 103 over iPR3-Val 103 in a direct ELISA (Fig. 3C) . By contrast, murine anti-PR3 moAbs (PR3G-2, MCPR3-3 and WGM2) exhibited equal binding to both antigens in the direct ELISA (Fig 3D) .
Remote-mutation-induced selective binding of moANCA518 to Epitope 3 on iHm5-Val 103
To identify the epitope(s) recognized by moANCA518 on iHm5-Val 103 in a capture ELISA, we used epitope-specific moAbs to capture iHm5-Val 103 and block or modulate the binding of moANCA518 to the epitope that the moAb is raised against [19] . We found that PR3G-2, a moAb that recognizes Epitope 1 of PR3 [41] , did not affect binding of moANCA518 to iHm5-Val 103 ; whereas MCPR3-3 or WGM2, both of which recognize Epitope 3 of PR3 [19] , respectively decreased or abolished the moANCA518 binding (p < 0.01; Fig. 4A ). When using a PR3-ANCA-containing serum sample obtained from the same patient at the same study visit, from which the plasmablast expressing moANCA518 was generated, we observed similar effects of these moAbs on the reactivity of the PR3-ANCA serum sample with iHm5-Val 103 (Fig. 4B) .
These findings identified Epitope 3 on iHm5-Val 103 as the epitope for moANCA518 and for a significant proportion of PR3-ANCA present in the serum obtained at the same time as the moANCA518-generating plasmablast.
We further confirmed Epitope 3 of iHm5-Val 103 as the primary target for moANCA518
using Fabs from epitope-specific moAbs as inhibitors of binding of moANCA518 to iHm5-Val 103 using the anchor ELISA (Fig. 5A) . As expected, we observed the strongest inhibition when the Fab from moANCA518 was used to inhibit the moANCA518 binding. A strong inhibition was observed with the Fab from MCPR3-3 that targets Epitope 3 of PR3 [19] , whereas a relatively reduced inhibition was found with the Fab from MCPR3-2 that interacts primarily with Epitope 4 and to some extent with Epitope 3 as well [19, 24] . In addition, we found no effect of the Fab from MCPR3-7, which recognizes Epitope 5 [19, 31] , on the moANCA518 binding.
The above results demonstrate that moANCA518 recognizes Epitope 3 on iHm5-Val 103 .
More importantly, because Epitope 3 is on the opposite side of the chimeric mutation sites in Epitopes 1 and 5 on iHm5-Val 103 (Fig. 1) and has the same amino acid sequence as that of Epitope 3 on iPR3-Val 103 , our observation that moANCA518 recognizes Epitope 3 instead of Epitope 1 or 5 further indicates that the moANCA518 binding is conferred by an unexpected increase of the antigenicity in Epitope 3 induced by the distal mutations in Epitopes 1 and 5.
Remote-mutation-induced preferential binding of most PR3-ANCAs to Epitope 3 on iHm5-Val 103
To determine whether other PR3-ANCAs would preferentially bind to Epitope 3 on iHm5-Val 103 over iPR3-Val 103 due to the distal mutations in iHm5-Val 103 , we further evaluated serum or plasma samples from patients with AAV that had exhibited significant preferential reactivity with iHm5-Val 103 over iPR3-Val 103 as described in Section 3.1, and found that the Fabs from MCPR3-3 and moANCA518 inhibited significantly (p = 0.001 and 0.017, respectively) the reactivity of a representative PR3-ANCA-containing plasma sample to iHm5-Val 103 in the anchor ELISA (Fig. 5B) .
These results indicate that the preferential reactivity of PR3-ANCAs containing serum or plasma samples with iHm5-Val 103 can at least in part be explained by some PR3-ANCAs in these samples being sensitive to the change of antigenicity in Epitope 3 of iHm5-Val 103 induced by the distal mutations, just like moANCA518.
Discussion
In this study we show that about half of all PR3-ANCA positive sera displayed stronger binding to iHm5-Val 103 than to iPR3-Val 103 , indicating that iHm5-Val 103 has its clinical relevance and could be used as an antigen for more sensitive immunoassays for PR3-ANCA detection relative to the use of iPR3-Val 103 . Using iHm5-Val 103 we discovered a new human monoclonal PR3-ANCA, moANCA518, that binds preferentially to Epitope 3 on iHm5-Val 103 over iPR3-Val 103 as a consequence of an unexpected increase of the antigencity in Epitope 3 of iHm5-Val 103 that was induced by the three remote chimeric mutations in Epitopes 1 and 5.
Finally, we found that the majority of PR3-ANCA-positive plasma samples from patients with AAV with higher reactivities to iHm5-Val 103 than to iPR3-Val 103 also displayed similar preferential binding to Epitope 3 of iHm5-Val 103 as moANCA518.
The PR3 variant iPR3-Val 103 has been used for two decades as a standard PR3 antigen for sensitive and specific PR3-ANCA detection by immunoassay [7, 21, [24] [25] [26] [27] [28] [29] . The iHm5-Val 103 variant and its "inverse"-chimeric counterpart, iMh5-Val 103 (formerly referred to as Mh5) were originally designed for discontinuous epitope mapping and structure-function analysis studies [19] . When we used iHm5-Val 103 for the of anti-PR3 moAbs and PR3-ANCAs, we expected that some PR3-ANCA positive sera would display reduced binding to iHm5-Val 103 which would have allowed the conclusion that some PR3-ANCAs in such a serum sample target Epitope 5
(possibly with Epitope 1 as well). Instead, we identified no loss of binding to iHm5-Val 103 compared to iPR3-Val 103 by any PR3-ANCA positive sera from patients with PR3-ANCA positive AAV, but that the sera either bound equally well to both of these antigens or displayed substantially increased binding to iHm5-Val 103 . Consequently, we first addressed the question whether iHm5-Val 103 represents a useful antigen for more sensitive immunoassays for PR3-ANCA detection. We found that low-level PR3-ANCAs can be detected more readily in some patients with PR3-ANCA positive AAV without generating a significant number of false positive results in patients with MPO-ANCA positive vasculitis or octogenarians without AAV.
However, we were unable to detect recurrent PR3-ANCAs earlier in trial participants who had serial follow-up PR3-ANCA measurements at quarterly intervals [33] [34] [35] . Whether the use of iHm5-Val 103 might be clinically useful for early detection of PR3-ANCA seroconversion after rituximab therapy in chronically relapsing patients with PR3-ANCA associated AAV, would require a dedicated prospective study with PR3-ANCA measurements at narrower intervals.
The identification of moANCA518 with selective binding to iHm5-Val 103 was a fortuitous finding that allowed us to further investigate the observation of increased reactivity of many PR3-ANCA-positive sera with iHm5-Val 103 . The PR3-ANCA response is thought to be an oligoclonal immune response as serum samples from patients have been documented to contain PR3-ANCAs binding to more than one epitope [19, 44] . The systematic analysis of the binding of moANCA518 to iHm5-Val 103 using moAbs with defined PR3-ANCA epitope recognition as inhibitors of binding led to another surprise, namely, that moANCA518 does not bind to the surface region of PR3 where the mutations that differentiate iHm5-Val 103 from iPR3-Val 103 are located, but to Epitope 3 of iHm5-Val 103 which is located on the opposite side of the iHm5-Val 103 structure from the side where the mutations were introduced (Fig. 1) . Thus, we identified a unique PR3-ANCA reactivity to an epitope that is conserved in its amino-acid sequence, yet must display a substantial structural/dynamic change, sufficient to confer antibody specificity. This effect thus appears akin to an allosteric effect; only in this case, such an allosteric effect is not generated by the distal binding of a ligand but generated by distal mutations.
This type of mutation allosteric effect has implications for the design and interpretation of site-directed mutagenesis studies because mutation effects can go far beyond the mutation sites; in the present case, a site that is 30 Å away from the mutation sites according to the crystal structure of human PR3 [45] . Although further studies are needed to explain how mutations (such as the chimeric mutations in iHm5-Val 103 ) can increase the antigenicity of a remote epitope (such as Epitope 3 on iHm5-Val 103 ), our present finding that PR3-ANCAs bind to epitopes of a folded rather than denatured antigen that is conducive to the mutation allosteric effect or "cross talk" of mutations suggests a possible mechanism of activation of a latent epitope or potentiation of a weak epitope by distal mutations. This has relevance for the etiologies of antibody-mediated autoimmune diseases and may lead to novel therapeutic approaches aimed at interfering with pathogenic antibody-antigen interactions.
Conclusions
This study shows that iHm5-Val 103 is a clinically relevant PR3 mutant and can be used as insights into novel treatment strategies for these diseases.
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Figure legends
B.
A representative PR3-ANCA positive patient plasma sample was selected from a cohort based on the differential binding results displayed to iHm5-Val 103 and iPR3-Val 103 in the anchor ELISA. Epitope specificity of the Fabs from moAbs used as inhibitors of binding is as follows:
MCPR3-3 for Epitope 3, MCPR3-2 for Epitope 4 and part of Epitope 3, and MCPR3-7 for Epitope 5. The control Fab corresponds to a mouse IgG1 Fab. Inhibition of PR3-ANCA binding to iHm5-Val 103 by Fabs that bind Epitope 3 was observed: MCPR3-3 (p = 0.001, in comparison with the control) and moANCA518 (p = 0.017, in comparison with the control). Fab -antigen binding fragment; moAb -monoclonal antibody; OD -optical density. 
